INGN
Inogen·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Ample Liquidity
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About INGN
Inogen, Inc.
A medical technology company offering innovative respiratory products for use in the homecare setting
Healthcare Equipment and Supplies
11/27/2001
02/14/2014
NASDAQ Stock Exchange
766
12-31
Common stock
859 Ward Drive, Goleta, California, 93111
--
Inogen, Inc., established in Delaware on November 27, 2001, is a pharmaceutical technology company that develops, produces and sells new portable medical oxygen concentrators for long-term supplementary oxygen therapy patients with chronic obstructive pulmonary disease (COPD) and their chronic respiratory diseases. The ownership of the Inogen One system is designed to address the problems of the traditional oxygen therapy model (oxygen delivery model) that affect the quality of life and defects of patients.
Earnings Call
Q1/2025
Estimate EPS-0.25
Actual EPS-0.11
Estimate Revenue79.57M
Actual Revenue82.30M
Inogen's Q1 2025: Navigating Contradictions in Revenue, Market Strategy, and Patient Dynamics
May 08,2025 07:33
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
INGN has released its 2025 Q3 earnings. EPS was reported at -0.2, versus the expected -0.09, missing expectations. The chart below visualizes how INGN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
INGN has released its 2025 Q3 earnings report, with revenue of 92.39M, reflecting a YoY change of 4.00%, and net profit of -5.29M, showing a YoY change of 11.22%. The Sankey diagram below clearly presents INGN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
